by GlobeNewsWire | Aug 9, 2016 | Globe Newswire
CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced dosing of the first...
by GlobeNewsWire | Aug 4, 2016 | Globe Newswire
CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its second quarter...
by GlobeNewsWire | Jun 29, 2016 | Globe Newswire
CAMBRIDGE, Mass., June 29, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that...
by GlobeNewsWire | Jun 22, 2016 | Globe Newswire
Data Presented at the 20th International Congress of Parkinson’s Disease & Movement Disorders in Berlin, Germany VY-AADC01 Continues to Demonstrate Safety with Increasing Coverage of Targeted Regions of the Brain Phase 1b Study On Track to Report Interim Motor...
by GlobeNewsWire | Jun 21, 2016 | Globe Newswire
CAMBRIDGE, Mass., June 21, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the...